Rezul'taty klinicheskogo issledovaniya preparata Infibeta (II–III faza). Rekomendatsii po perevodu patsientov s rasseyannym sklerozom na bioanalogi
- Authors: Popova E.V1, Boyko A.N1, Vasil'ev A.V2, Davydovskaya M.V1, Zavalishin I.A2, Kotov S.V3, Krotenkova M.V2, Khachanova N.V1, Sharanova S.N1, Shchur S.G1, Yakushina T.I3
-
Affiliations:
- Московский городской центр рассеянного склероза (ГКБ №11)
- Научный центр неврологии РАМН
- ГУ Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского
- Issue: Vol 14, No 2 (2012)
- Pages: 120-125
- Section: Articles
- URL: https://journal-vniispk.ru/2075-1753/article/view/93632
- ID: 93632
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
E. V Popova
Московский городской центр рассеянного склероза (ГКБ №11)
A. N Boyko
Московский городской центр рассеянного склероза (ГКБ №11)
A. V Vasil'ev
Научный центр неврологии РАМН
M. V Davydovskaya
Московский городской центр рассеянного склероза (ГКБ №11)
I. A Zavalishin
Научный центр неврологии РАМН
S. V Kotov
ГУ Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского
M. V Krotenkova
Научный центр неврологии РАМН
N. V Khachanova
Московский городской центр рассеянного склероза (ГКБ №11)
S. N Sharanova
Московский городской центр рассеянного склероза (ГКБ №11)
S. G Shchur
Московский городской центр рассеянного склероза (ГКБ №11)
T. I Yakushina
ГУ Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского
References
- Гусев Е.И., Демина Т.Л., Бойко А.Н. Рассеянный склероз. М., 1997.
- Paty D.W., Hartung H.P., Ebers G.C. et al. Management of relapsing - remitting multiple sclerosis: diagnosis and treatment guidelines. Eur J Neurol 1999; 6 (Suppl. 1): 1–35.
- Gaines A.R., Varrichio F. Interferon beta-1b injection site reactions and necrosis. Multiple Sclerosis 1998; 4: 70–3.
- IFNB Multiple Sclerosis Study Group. Interferon - beta-1b is effective in relapsing - remitting multiple sclerosis. I. Clinical results of a multicenter randomized, double - blind, placebo - controlled trial. Neurology 1993; 43: 655–61.
- Rudick R.A., Sibley W, Durelli L. Treatment of multiple sclerosis with type I interferons. Multiple sclerosis, Advances in Clinical Trial Design, Treatment and Future Perspectives. Springer-Verlag, London, 1996; p. 230–1.
- Munschauer F.E., Kinkel R.P. Managing side effects of Interferon - beta in patients with relapsing - remitting multiple sclerosis. Clin Therap 1997; 19: 883–93.
- Lyseng-Williamson K.A. Subcutaneous recombinant interferon - beta - 1a (Rebif): a review of its use in relapsing - remitting multiple sclerosis. K.Lyseng-Williamson, D.Murdoch. Drugs 2005; 65 (9): 1295–312.
- Kappos L. New aspects in treatment of multiple sclerosis with interferon beta–1b. J Neurology 2004; 251 (4): 1.
- IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon - beta - 1b in the treatment of MS; final outcome of the randomized controlled trial. Neurology 1995; 45: 1277–85.
- Lublin F.D., Whitaker J.N., Eidelman B.H. et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996; 46: 12–8.
- Walther E.U., Dang T, Hohlfeld R. Management of side effects of beta - interferon therapy in MS. Int MS J 1999; 5: 65–70.
- Bayas A, Reickmann P. Managing the Adverse Effects of Interferon - b Therapy in Multiple Sclerosis. Drug Safety 2000; 22: 149–59.
- Durelli L, Ogerro A, Verdun E et al. Does high - dose interferon - beta - 1b improve clinical response in more severely disabled multiple sclerosis patients? J Neurol Sci 2000; 178: 37–41.
- Siegert R.J., Abernethy D.A. Depression in multiple sclerosis: a review. J Neurology Neurosurgery and Psychiatry 2005; 76: 469–75.
- Patten S.B., Metz L.M. Interferon beta-1a and depression in relapsing - remitting MS: an analysis of depression data from the PRISMS clinical trial. Mult Scler 2001; 7 (4): 243–8.
- The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing - remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double - blind, placebo - controlled trial. Neurology 1993; 43 (4): 655–61.
- Filippi M, Tortorella C, Bozzali M. Normal appearing white matter changes in multiple sclerosis. The contribution of magnetic resonance techniques. Multiple Sclerosis 1999; 5: 273–82.
- Rovaris M, Agosta F, Sormani M.P. et al. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium - term follow - up study. Brain 2003; 126 (10): 2323–32.
- Martinelli B.F., Rovaris M, Comi G, Filippi M. The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials. Mult Scler 2004; 10 (4): 341–7.
- Castelijns J, Barkhof F. Magnetic resonance (MR) imaging as a marker for multiple sclerosis. Biomed Pharmacother 1999; 53 (8): 351–7.
- Fazekas F, Barkhof F, Filippi M et al. The contribution of magnetic resonance imaging to the diagnosis multiple sclerosis. Neurology 1999; 53: 448–56.
- Kesselring J, Lassmann H. Pathogenesis Multiple sclerosis. Ed. J.Kesselring. Cambridge University Press 1997; p. 54–62.
- Zivadinov R, Cox J.L. Neuroimaging in multiple sclerosis. Int Rev Neurobiol 2007; 79: 449–74.
- The North Fmerican Study Group on Interferon beta-1b in Secondary-Progressive MS. Interferonbeta-1binsecondaryprogressiveMS. Neurology 2004; 63: 1788–95.
- Гусев Е.И., Бойко А.Н. Рассеянный склероз: от изучения иммунопатогенеза к новым методам лечения. М., 2001.
Supplementary files
